Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 5 Methoxy N,n Dimethyltryptamine
2. 5-methoxy-n,n-dimethyltryptamine
3. Methoxydimethyltryptamine
4. Methoxydimethyltryptamines
5. Methylbufotenin
6. N,n Dimethyl 5 Methoxytryptamine
1. 1019-45-0
2. 5-methoxy-n,n-dimethyltryptamine
3. Methoxybufotenin
4. O-methylbufotenine
5. 5-meo-dmt
6. Meodmt
7. Methylbufotenine
8. 5-methoxydimethyltryptamine
9. 3-(2-dimethylaminoethyl)-5-methoxyindole
10. Bufotenine, O-methyl-
11. 2-(5-methoxy-1h-indol-3-yl)-n,n-dimethylethanamine
12. 1h-indole-3-ethanamine, 5-methoxy-n,n-dimethyl-
13. Ct 4334
14. Methoxydimethyltryptamines
15. 5-methoxy-n,n-dimethyl-1h-indole-3-ethanamine
16. Nsc 88624
17. 5-methoxy-n,n-dimethyl-1h-indole-3-ethylamine
18. Indole, 3-(2-(n,n-dimethylamino)ethyl)-5-methoxy-
19. X0mkx3gwu9
20. 3-(2-(n,n-dimethyl)aminoethyl)-5-methoxyindole
21. Chembl7257
22. Mls000069438
23. Chebi:2086
24. Indole, 3-(2-(dimethylamino)ethyl)-5-methoxy-
25. Indole, 3-[2-(dimethylamino)ethyl]-5-methoxy-
26. 3-[2-(n,n-dimethylamino)ethyl]-5-methoxy-indole
27. Nsc-88624
28. Smr000059066
29. 3-(2-(n,n-dimethylamino)ethyl)-5-methoxyindole
30. 3-[2-(n,n-dimethylamino)ethyl]-5-methoxyindole
31. 5-ome-dmt
32. Einecs 213-813-2
33. Unii-x0mkx3gwu9
34. Brn 0164771
35. Maybridge3_000045
36. Lopac-m-2381
37. Cid_1832
38. Lopac0_000724
39. Oprea1_596468
40. Gtpl145
41. 5-22-12-00027 (beilstein Handbook Reference)
42. Schembl132733
43. 2-(5-methoxy-1h-indol-3-yl)-n,n-dimethyl-ethanamine
44. Bdbm30707
45. Zinc57152
46. Dtxsid70144324
47. [2-(5-methoxy-1h-indol-3-yl)-ethyl]-dimethyl-amine
48. Hms1431c01
49. Hms2235c20
50. Hms3370m04
51. N,n-dimethyl-5-methoxy Tryptamine
52. Nsc88624
53. Pdsp1_000032
54. Pdsp1_000447
55. Pdsp2_000032
56. Pdsp2_000445
57. Stk368074
58. 5-methoxy-n-dimethyltryptamine
59. Akos005203483
60. Bufotenine, 5-methoxydimethyltryptamine
61. Ccg-204809
62. Db14010
63. Sdccgmls-0003129.p003
64. Idi1_011432
65. Wln: T56 Bmj D2n1&1 Go1
66. Ncgc00015654-01
67. Ncgc00015654-02
68. Ncgc00015654-03
69. Ncgc00015654-04
70. Ncgc00015654-05
71. Ncgc00015654-06
72. Ncgc00023288-03
73. Ncgc00023288-04
74. Indole,n-dimethylamino)ethyl]-5-methoxy-
75. Db-005455
76. N,n-dimethyl-5-methoxytryptamine, Free Base
77. C08309
78. D-5380
79. [2-(5-methoxy-1h-indol-3-yl)ethyl]dimethylamine
80. 019d450
81. 2-(5-methoxy-1h-indol-3-yl)ethyl-dimethyl-amine
82. 5-methoxyindole 3-(2-(n,n-dimethylamino)ethyl)
83. L000724
84. Q570757
85. 2-(5-methoxy-1h-indol-3-yl)-ethyl-dimethyl-amine
86. Brd-k34224286-001-07-1
87. 2-(5-methoxy-1h-indol-3-yl)-n,n-dimethylethanamine #
88. 5-meo-dmt Solution, 1.0 Mg/ml In Methanol, Certified Reference Material
| Molecular Weight | 218.29 g/mol |
|---|---|
| Molecular Formula | C13H18N2O |
| XLogP3 | 1.5 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 4 |
| Exact Mass | 218.141913202 g/mol |
| Monoisotopic Mass | 218.141913202 g/mol |
| Topological Polar Surface Area | 28.3 Ų |
| Heavy Atom Count | 16 |
| Formal Charge | 0 |
| Complexity | 220 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
N,n-dimethyl-5-methoxytryptamine has known human metabolites that include Bufotenine.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
Drugs in Development
Details:
The procceds will used to fund the clinical development of company's lead product GH001 (mebufotenin), which is being evaluated in patients with bipolar II disorder & other Psychiatry disorder.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Brand Name: GH001
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Cantor Fitzgerald
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 04, 2025
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Cantor Fitzgerald
Deal Size : $150.0 million
Deal Type : Public Offering
GH Research Announces Pricing of $150 Million Public Offering
Details : The procceds will used to fund the clinical development of company's lead product GH001 (mebufotenin), which is being evaluated in patients with bipolar II disorder & other Psychiatry disorder.
Product Name : GH001
Product Type : Controlled Substance
Upfront Cash : Undisclosed
February 04, 2025
Details:
The procceds will used to fund the clinical development of company's lead product GH001 (mebufotenin), which is being evaluated in patients with bipolar II disorder & other Psychiatry disorder.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Brand Name: GH001
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Cantor Fitzgerald
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 03, 2025
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Cantor Fitzgerald
Deal Size : $150.0 million
Deal Type : Public Offering
GH Research Announces Proposed Public Offering
Details : The procceds will used to fund the clinical development of company's lead product GH001 (mebufotenin), which is being evaluated in patients with bipolar II disorder & other Psychiatry disorder.
Product Name : GH001
Product Type : Controlled Substance
Upfront Cash : Undisclosed
February 03, 2025
Details:
GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. It is being evaluated for the treatment of treatment-resistant depression.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Brand Name: GH001
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 03, 2025
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GH Research’s GH001 Meets Primary Endpoint in Phase 2b TRD Trial (-15.5 MADRS)
Details : GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. It is being evaluated for the treatment of treatment-resistant depression.
Product Name : GH001
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 03, 2025
Details:
GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. It is being evaluated for the treatment of treatment-resistant depression.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Brand Name: GH001
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 31, 2025
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GH Research to Provide Update on Phase 2b Trial with GH001 in TRD
Details : GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. It is being evaluated for the treatment of treatment-resistant depression.
Product Name : GH001
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 31, 2025
Details:
GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. It is being evaluated for the treatment of postpartum depression.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Brand Name: GH001
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 10, 2025
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GH Research Meets Primary Endpoint in Phase 2a Trials of GH001
Details : GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. It is being evaluated for the treatment of postpartum depression.
Product Name : GH001
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 10, 2025
Details:
BMND08 (5-MeO-DMT) is a 5-HT1A receptor agonist, small molecule drug candidate. It is being evaluated for the treatment of depression & anxiety in alzheimer’s disease.
Lead Product(s): Mebufotenin
Therapeutic Area: Neurology Brand Name: BMND08
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 29, 2024
Lead Product(s) : Mebufotenin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biomind Reports Positive Phase 2 Results of BMND08 for Depression in Alzheimer’s Disease
Details : BMND08 (5-MeO-DMT) is a 5-HT1A receptor agonist, small molecule drug candidate. It is being evaluated for the treatment of depression & anxiety in alzheimer’s disease.
Product Name : BMND08
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 29, 2024
Details:
GH001, is formulated for mebufotenin (5-MeO-DMT) administration via a proprietary inhalation approach, which is investigated for the treatment of treatment-resistant depression.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Brand Name: GH001
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 29, 2023
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GH001, is formulated for mebufotenin (5-MeO-DMT) administration via a proprietary inhalation approach, which is investigated for the treatment of treatment-resistant depression.
Product Name : GH001
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 29, 2023
Details:
BMND08 is a proprietary sublingual formulation of 5-Metoxi-N,N-dimethyltryptamine ("5-MeO-DMT"), being investigated as a potential treatment of anxiety and depression in alzheimer’s disease.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Brand Name: BMND08
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 25, 2023
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BMND08 is a proprietary sublingual formulation of 5-Metoxi-N,N-dimethyltryptamine ("5-MeO-DMT"), being investigated as a potential treatment of anxiety and depression in alzheimer’s disease.
Product Name : BMND08
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 25, 2023
Details:
BMND08 is an oral formulation of a natural psychedelic called 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for the potential treatment of depression and anxiety in Alzheimer’s disease.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Brand Name: BMND08
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 28, 2022
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BMND08 is an oral formulation of a natural psychedelic called 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for the potential treatment of depression and anxiety in Alzheimer’s disease.
Product Name : BMND08
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 28, 2022
Details:
BMND08 (5-Methoxy-N,N-dimethyltryptamine) novel drug candidate which may allow us to address a new line of development to attenuate depression and anxiety states in patients with Alzheimer’s-type cognitive impairment.
Lead Product(s): Mebufotenin
Therapeutic Area: Psychiatry/Psychology Brand Name: BMND08
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 26, 2022
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BMND08 (5-Methoxy-N,N-dimethyltryptamine) novel drug candidate which may allow us to address a new line of development to attenuate depression and anxiety states in patients with Alzheimer’s-type cognitive impairment.
Product Name : BMND08
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
66
PharmaCompass offers a list of Mebufotenin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Mebufotenin manufacturer or Mebufotenin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Mebufotenin manufacturer or Mebufotenin supplier.
PharmaCompass also assists you with knowing the Mebufotenin API Price utilized in the formulation of products. Mebufotenin API Price is not always fixed or binding as the Mebufotenin Price is obtained through a variety of data sources. The Mebufotenin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Mebufotenin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Mebufotenin, including repackagers and relabelers. The FDA regulates Mebufotenin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Mebufotenin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Mebufotenin supplier is an individual or a company that provides Mebufotenin active pharmaceutical ingredient (API) or Mebufotenin finished formulations upon request. The Mebufotenin suppliers may include Mebufotenin API manufacturers, exporters, distributors and traders.
Mebufotenin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Mebufotenin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Mebufotenin GMP manufacturer or Mebufotenin GMP API supplier for your needs.
A Mebufotenin CoA (Certificate of Analysis) is a formal document that attests to Mebufotenin's compliance with Mebufotenin specifications and serves as a tool for batch-level quality control.
Mebufotenin CoA mostly includes findings from lab analyses of a specific batch. For each Mebufotenin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Mebufotenin may be tested according to a variety of international standards, such as European Pharmacopoeia (Mebufotenin EP), Mebufotenin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Mebufotenin USP).
